妊娠期糖尿病筛查的整群随机非劣效现场试验
该整群随机非劣效现场试验纳入35528名孕妇,比较5种预设筛查方案(早孕期空腹血糖阈值5.1或5.6 mmol/L,联合中孕期一步法或两步法)与严格IADPSG标准对母婴结局的非劣效性。结果显示宽松方案B、C、D、E在巨大儿和初次剖宫产上总体非劣效于方案A,但方案E在初次剖宫产上未显示非劣效。
要点
- 各方案诊断GDM比例:A 21.9%、B 10.5%、C 12.1%、D 19.4%、E 8.1%。
- 宽松方案B、C、D、E对主要结局满足非劣效,但E对初次剖宫产未达非劣效。
- 两步法与一步法筛查在不良妊娠结局调整后比值比无统计学显著差异。
核心结论
- IADPSG的GDM定义显著增加了GDM诊断率,但较宽松的筛查方案在母婴不良结局方面不劣于其他标准。
研究设计与样本
- 整群随机非劣效现场试验,纳入35528名孕妇,按5种预设方案(A、B、C、D、E)进行两阶段GDM筛查。
主要发现
- 诊断为GDM并分配至方案A、B、C、D、E的孕妇百分比分别为21.9%、10.5%、12.1%、19.4%和8.1%。
- 意向性分析显示,较宽松方案B、C、D、E与方案A相比满足非劣效性,但方案E与A比较在初次剖宫产上未显示非劣效。
- 巨大儿和剖宫产的比值比(95% CI)分别为:B 1.01(0.95-1.08)、0.85(0.56-1.28);C 1.03(0.73-1.47)、1.16(0.88-1.51);D 0.89(0.68-1.17)、0.94(0.61-1.44);E 1.05(0.65-1.69)、1.33(0.82-2.00),均与A比较。
- 考虑多重性调整后,两步法与一步法筛查相比,不良妊娠结局的调整后比值比无统计学显著差异。
关键数值与推荐
- 非劣效性界值为比值比1.7。
- 早孕期空腹血糖阈值:方案A、D为5.1 mmol/L(92 mg/dL),方案B、C、E为5.6 mmol/L(100 mg/dL)。
- 中孕期一步法:方案A和C中任一血糖值超标即诊断GDM,方案B需两个或以上血糖值超标;两步法:方案D和E。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Although it is well-acknowledged that gestational diabetes mellitus (GDM) is associated with the increased risks of adverse pregnancy outcomes, the optimal strategy for screening and diagnosis of GDM is still a matter of debate. OBJECTIVE: This study was conducted to demonstrate the noninferiority of less strict GDM screening criteria compared with the strict International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria with respect to maternal and neonatal outcomes. METHODS: A cluster randomized noninferiority field trial was conducted on 35 528 pregnant women; they were scheduled to have 2 phases of GDM screening based on 5 different prespecified protocols including fasting plasma glucose in the first trimester with threshold of 5.1 mmol/L (92 mg/dL) (protocols A, D) or 5.6 mmol/L (100 mg/dL) (protocols B, C, E) and either a 1-step (GDM is defined if one of the plasma glucose values is exceeded [protocol A and C] or 2 or more exceeded values are needed [protocol B]) or 2-step approach (protocols D, E) in the second trimester. Guidelines for treatment of GDM were consistent with all protocols. Primary outcomes of the study were the prevalence of macrosomia and primary cesarean section (CS). The null hypothesis that less strict protocols are inferior to protocol A (IADPSG) was tested with a noninferiority margin effect (odds ratio) of 1.7. RESULTS: The percentages of pregnant women diagnosed with GDM and assigned to protocols A, B, C, D, and E were 21.9%, 10.5%, 12.1%, 19.4%, and 8.1%, respectively. Intention-to-treat analyses satisfying the noninferiority of the less strict protocols of B, C, D, and E compared with protocol A. However, noninferiority was not shown for primary CS comparing protocol E with A. The odds ratios (95% CI) for macrosomia and CS were: B (1.01 [0.95-1.08]; 0.85 [0.56-1.28], C (1.03 [0.73-1.47]; 1.16 [0.88-1.51]), D (0.89 [0.68-1.17]; 0.94 [0.61-1.44]), and E (1.05 [0.65-1.69]; 1.33 [0.82-2.00]) vs A. There were no statistically significant differences in the adjusted odds of adverse pregnancy outcomes in the 2-step compared with the 1-step screening approaches, considering multiplicity adjustment. CONCLUSIONS: The IADPSG GDM definition significantly increased the prevalence of GDM diagnosis. However, the less strict approaches were not inferior to other criteria in terms of adverse maternal and neonatal outcomes.
引用
- Ramezani Tehrani F, Behboudi-Gandevani S, Farzadfar F, et al. A Cluster Randomized Noninferiority Field Trial of Gestational Diabetes Mellitus Screening. J Clin Endocrinol Metab. 2022. PMID: 35325164. doi:10.1210/clinem/dgac181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。